TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03820011

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PEM+
Description: PEM+ is a five-step recursive process (i.e., the caregiver can repeat the five-step process to create as many intervention plans for their child as needed, relative to the number of activities in which change is desired based on the YC-PEM e-PRO, and it offers tiered support to the user during completion (tier 1: frequently asked questions available in the application, tier 2: support provided by email, tier 3: support provided by phone).
Study: NCT02701205

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept
Description: Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: etanercept (half dose)
Description: Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 25mg twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: two vials of placebo twice a week by subcutaneous injection for 12 weeks, At the end of the first 12 weeks, all subjects will be treated with Recombinant Human TNF Receptor-Ig Fusion Protein for Injection 50 mg once a week for an additional 12 weeks.
Study: NCT02340884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Promoting Resilience In Stress Management (PRISM)
Description: The brief format of the PRISM intervention involves 4, 50-minute, one-on-one sessions approximately 2 weeks apart, plus a 5th parent-inclusive session 2-4 weeks following session #4. These are complimented with age-specific handouts describing the skills and opportunities to practice them, as well as weekly (text- or email based) check-ins from study staff and in-person booster sessions once monthly. Specifically, the intervention incorporates four primary skills: 1) stress management/mindfulness; 2) goal-setting; 3) cognitive restructuring; and, 4) meaning-making/benefit finding.
Study: NCT02710188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HTL0009936 modified release
Description: HTL0009936 modified release

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HTL0009936 immediate release
Description: HTL0009936 immediate release
Study: NCT04298619

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard cohort: Clinical lab follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Standard cohort: Clinical lab follow-up

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging cohort: integrated imaging follow-up
Study: NCT05812326

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJMUC1- PD-1 gene knockout anti-MUC1 CAR-T cells
Description: AJMUC1 is a genetically modified T cell therapeutic product targeting the aberrantly glycosylated MUC1 protein. CAR targeting MUC1 is introduced into autologous T cells by lentiviral vector, so that T cells expressing the receptor can recognize and kill MUC1 positive tumor cells. Preclinical studies have shown that binding of scFv targeting MUC1 to the MUC1 epitope on the surface of the target cell can induce the costimulatory CD28 and CD3ζ costimulatory domains to activate downstream signaling pathways and promote T cell activation and expansion. Activated CAR-T cells secrete a series of inflammatory cytokines and chemokines, leading to apoptosis and necrosis of target tumor cells. Following introduction of a CAR structure, the PD-1 gene of CAR-T cells is knocked out using CRISPR/Cas9, so that the CAR-T cell does not express PD-1, resulting in improved tumor killing efficiency of AJMUC due to the release of inhibition in the signaling pathway PD-1/PD-L1 in the tumor microenvironment.
Study: NCT01011114

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cinacalcet
Description: cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: cinacalcet, 30 mg daily, titrated to achieve serum phosphorus of 2.5 mg/dl, versus placebo, similarly titrated.
Study: NCT03942224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Daratumumab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given IV and PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Given PO
Study: NCT02544854

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion will be started after inhalational induction by manual infusion by the following scheme:~1. First 15 minutes: 15 mg/kg/min~2. 16 to 30 minutes: 13 mg/kg/min~3. 31 to 60 minutes: 11 mg/kg/min~4. 61 to 120 minutes: 10 mg/kg/min Dose will be titrated to maintain BIS between 40 - 50.~Venous sampling for plasmatic levels of propofol measuring will be made at the following moments:~1. 5, 15 and 25 minutes of starting infusion,~2. 1, 3, 5, 7, 9 and 12 minutes of bolus and,~3. 5, 25, 60 and 120 minutes of infusion ended.
Study: NCT01357343

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic
Description: Spinal manipulation and active and passive therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Chiropractic
Description: Spinal manipulation and active and passive therapy.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture needling, moxa, Tui Na and cupping.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: Acupuncture needling, moxa, Tui Na and cupping.
Study: NCT00335166

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pardaprunox
Description: 12-42 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pramipexole
Description: 1.5-4.5 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo
Study: NCT00744016

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Granulated mesalamine
Description: 0.375 g of mesalamine granules were encapsulated in a hard gelatin shell. 1.5 g of eMG (4 capsules) were administered orally QD, in the morning

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules (4 capsules) were administered orally QD, in the morning
Study: NCT02726113

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cholecalciferol
Description: softgels 4000 IU daily for approximately two months prior to surgery (prostatectomy).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: softgel containing no active ingredient daily for approximately two months prior to surgery (prostatectomy).
Study: NCT03866148

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reveal LINQ
Description: Insertion of monitoring device called Reveal-LINQ (an implantable loop recorder)
Study: NCT00030615

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: decitabine
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00790179

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
Description: 0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
Description: 0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: continuous infusion of ropivacaine via CLPB vs. CFB vs IV PCA
Description: 0.5% Ropivacaine bolus of 30 ml. followed by ropivacaine 0.2%at 10 ml/hr via CLPB vs. CFB.~Hydromorphone 0.3 mg demand only every 10 minutes via IV PCA.
Study: NCT00593658

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pentoxifylline
Description: pentoxifylline extended release 800mg PO TID for 8 weeks
Study: NCT01641991

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® is a sterile, milky white suspension made from cell free filtrates of microaerophilic cultures of an avirulent, nonencapsulated strain of Bacillus anthracis, will be administered as a 0.50mL IM injection 6 month boost for all groups

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BioThrax®
Description: BioThrax® will be administered as: Arm A: 0.50mL SC injection on Days 0 and 14; Arm B: 0.50mL SC injection on Days 0 and 28; Arm C: 0.50mL SC injection on Days 0, 14 and 28; Arm D: 0.25 mL SC injection on Days 0, 14 and 28.
Study: NCT05256082

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: six-minutes-walking test
Description: Patients conducting a six-minutes-walking test

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: six-minutes-walking test
Description: Patients conducting a six-minutes-walking test
Study: NCT03685552

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prog: Purify-2
Description: Nutritional Supplements to be administered:~* Protein Shakes: one protein shake twice a day~* Probiotics (Bacillus Coagulans) once a day~* Biome NO+ ( blend of amino acids, specifically l-arginine and l-citrulline, combined with red beet root, grape polyphenol extract, vitamins and minerals) twice a day~* In.Form Purify ( blend of psyllium hull, inulin, L-glutamine, fruit, fruit extracts and zinc) twice a day
Study: NCT00765219

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 10-12 weekly sessions of CBT in person or over the telephone.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: 10-12 weekly sessions of CBT in person or over the telephone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Treatment as usual provided by participants' physician(s)
Study: NCT01585402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etidronate
Description: Didronel (etidronate disodium)- Didronel tablets contain either 200 mg or 400 mg of etidronate disodium, the disodium salt of (1-hydroxyethylidene) diphosphonic acid, for oral administration. This compound, also known as EHDP. regulates bone metabolism. It is a white powder, highly soluble in water. The 400 mg tablets are white capsule-shaped tablets with ED 400 on one side and G on the other side.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI Scan
Description: Visit on day 0 and visit at 36 month - Exploratory MRI studies may be employed to evaluate the lumen of the artery and degree of collateral vessels, given that the high degree of calcification is precluding that evaluation by CT.
Study: NCT03941847

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: music
Description: listening music
Study: NCT00434499

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Description: EGCG 400 mg by mouth twice/daily for 4 weeks duration.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EGCG
Description: EGCG 400 mg by mouth twice/daily for 4 weeks duration.
Study: NCT03803592

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dyadic MCS program
Description: In the first 4 weeks, the dyads will attend the center-based FTF sessions. Each session will last for 1.5 hours. In the first 60 minutes, MCS activities (e.g. reality orientation, calculation and drawing) will be led by an occupational therapist. Skills in delivering the MCS activities will also be taught to equip CG with skills in leading the home-based sessions later. CG will leave in the last 30 minutes to attend a psychoeducation group on caregiving (led by social workers) and the PWD will continue the session.~From week 5 onwards, The home based session (Week 5-15) will be delivered by the CG 3 times weekly at home (30 - 45min/ session).The sessions will be supplemented with weekly telephone follow-up and two FTF sharing sessions held on the 8th and 12th week over the period.
Study: NCT02590289

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-5000
Description: BBI-5000 low dose, middle dose, or high doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-5000
Description: BBI-5000 low dose, middle dose, or high doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-5000
Description: BBI-5000 low dose, middle dose, or high doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI-5000
Description: BBI-5000 low dose, middle dose, or high doses
Study: NCT02588469

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interventional group
Description: Venous compression leads to beneficial fluid regulation in OSA participants and appears as an efficient tool in OSA management.~To the investigators knowledge no study assess the impact of the cumulative effect of physical and venous compression program on upper airway resistances in obese teenager with OSA.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: Standard obesity care with physical activity program
Study: NCT02184676

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Analysis of early immune modifications
Description: * blood and stool sampling in parents during pregnancy (at enrollment, i.e. 7th-8th month of pregnancy)~* cord blood sampling~* stool sampling in mothers and newborns at birth (day 7)~* blood and stool sampling in children at the age of 8, 18, 30 and 42 months

Intervention type: OTHER
Group type: OTHER
Intervention: Collection of clinical and socio-demographic data
Description: 1. Questionnaire filled in by clinicians at enrollment and at birth~2. Self-administered questionnaire filled by parents at enrollment, at birth, and then at month 8, 18, 30 and 42
Study: NCT00544856

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: complex cognitive training

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: complex cognitive training
Study: NCT05407103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold Acupressure
Description: For the cold acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the cold acupressure pouches were kept in a freezer for 40 minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Warm Acupressure
Description: For the warm acupressure application, the researchers prepared pouches that were 3 cm long, 2 cm wide, and 1 cm high (3x2x1cm), and filled with cherry seeds - to retain heat for a longer time, hence the preference. Next, they fixed rubber bands to the pouches so that they stayed in place on the participants' hands during acupressure, and retain consistent pressure throughout. Lastly, the warm acupressure pouches were heated in a microwave at 600 W for one minute.
Study: NCT03168802

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRgFUS ablation
Description: Focus ultrasound ablation therapy under MRI navigation for facet joint syndrome.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency ablation therapy under C-arm navigation for facet joint syndrome.
Study: NCT02007954

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEBDOX
Description: DEBDOX, loaded with doxorubicin, is a device that utilizes beads in place of lipiodol to deliver the chemotherapy into the liver tumor. The device allows for continuous elution of doxorubicin into the liver tumor tissue. The advantages of this method of delivery in comparison to conventional TACE are that the beads are able to deliver a greater volume and concentration of the drugs to the tumor because of their unique ability to elute the drug over a period of several days. As a result of this unique delivery, systemic toxicity is significantly reduced. The potential advantages of the smaller beads are deeper penetration into the tumor bed, while avoiding premature proximal occlusion of vessels feeding the tumor, and more consistent dosing. These properties translate into greater potency of therapy and potentially improved patient survival.
Study: NCT03668535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder Filling
Description: Group A have a triple-way urethral catheter insertion before establishment of anaesthesia. Evaluation of the drained urine is done (including: amount, character, and simple for culture and sensitivity). Instillation of 200 ml sterile saline is done by 50 ml syringe through the irrigation way. The irrigation way is closed temporarily by artery forceps. After laparotomy the bladder may be deflated by 50 ml or further inflated by 50 ml if needed to allow comfortable dissection.
Study: NCT03710889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abaloparatide
Description: Abaloparatide is a novel, synthetic, 34 amino acid peptide designed to be a potent and selective activator of the PTH/PTH-related protein (PTHrP) type 1 receptor (PTHR1) signaling pathway with 41% homology to PTH\[1-34\] and 76% homology to human PTHrP\[1-34\].
Study: NCT01597726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: Misoprostol 400 mcg administered buccally approximately 3-6 hours prior to D\&E, repeated once 3 hours after the first dose if needed

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laminaria
Description: Laminaria tents inserted into the cervix 18 to 24 hours prior to D\&E
Study: NCT00578032

Intervention type: BEHAVIORAL
Intervention: Quality of Life Questionaires & Interview: EORTC QLQ C-30, EORTC QLQ H&N-35, Health Behaviors, Subjective Significance Questionnaire, Qualitative Assessment
Description: All patients will complete the predefined questionnaires at the following four time points along the course of their care: preoperative clinic visit, and 3 months (±1 month), 6 months (±1), and 9 months (1 and +3) post-operatively. Completion of the questionnaires should take approximately 30 minutes
Study: NCT03668535

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bladder deflation
Description: Group B have Foley's catheter is inserted as usual. The catheter is connected freely to urinary bag.
Study: NCT04511221

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium animals subsp. lactis BL04
Description: One 15mg capsule taken orally each day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One 15mg capsule taken orally each day